Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aptevo Therapeutics (APVO) Research & Development (2016 - 2025)

Aptevo Therapeutics (APVO) has disclosed Research & Development for 11 consecutive years, with $3.5 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 8.89% to $3.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.5 million through Dec 2025, up 1.13% year-over-year, with the annual reading at $14.5 million for FY2025, 1.13% up from the prior year.
  • Research & Development hit $3.5 million in Q4 2025 for Aptevo Therapeutics, down from $4.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $5.5 million in Q2 2023 to a low of $3.1 million in Q3 2024.
  • Historically, Research & Development has averaged $4.1 million across 5 years, with a median of $4.0 million in 2023.
  • Biggest five-year swings in Research & Development: skyrocketed 41.32% in 2023 and later tumbled 33.3% in 2024.
  • Year by year, Research & Development stood at $4.5 million in 2021, then rose by 2.88% to $4.7 million in 2022, then decreased by 23.17% to $3.6 million in 2023, then rose by 8.05% to $3.9 million in 2024, then fell by 8.89% to $3.5 million in 2025.
  • Business Quant data shows Research & Development for APVO at $3.5 million in Q4 2025, $4.0 million in Q3 2025, and $3.3 million in Q2 2025.